Microbiota-Gut-Brain Axis: New Therapeutic Opportunities

• Published in: Annual review of pharmacology and toxicology Vol. 60; no. 1; pp. 477 - 502
• Main Authors: Long-Smith, Caitríona, O'Riordan, Kenneth J, Clarke, Gerard, Stanton, Catherine, Dinan, Timothy G, Cryan, John F
• Format: Journal Article
• Language: English
• Published: United States Annual Reviews 06-01-2020
• Subjects: microbiota-gut-brain axis; prebiotic; probiotic; psychobiotic; microbiota-gut-brain axis; probiotic; prebiotic; psychobiotic
• ISSN: 0362-1642; 1545-4304
• DOI: 10.1146/annurev-pharmtox-010919-023628

The traditional fields of pharmacology and toxicology are beginning to consider the substantial impact our gut microbiota has on host physiology. The microbiota-gut-brain axis is emerging as a particular area of interest and a potential new therapeutic target for effective treatment of central nervous system disorders, in addition to being a potential cause of drug side effects. Microbiota-gut-brain axis signaling can occur via several pathways, including via the immune system, recruitment of host neurochemical signaling, direct enteric nervous system routes and the vagus nerve, and the production of bacterial metabolites. Altered gut microbial profiles have been described in several psychiatric and neurological disorders. Psychobiotics, live biotherapeutics or substances whose beneficial effects on the brain are bacterially mediated, are currently being investigated as direct and or adjunctive therapies for psychiatric and neurodevelopmental disorders and possibly for neurodegenerative disease, and they may emerge as new therapeutic options in the clinical management of brain disorders.